Roivant Sciences
ROIV
34.75
-0.78
-2.20%
Roivant Sciences
US · ROIV
#747 by market cap
Listed 1970
34.75
-0.78
-2.20%
Live - 5344 symbols - heartbeat 373s ago
· 2026-10-08 08:13
Pre-market
34.11
-1.84%
After-hours
35.06
+0.91%
Overnight
34.55
-0.58%
- Market cap
- 25.10B
- P/E (TTM)i
- -73.94
- P/Bi
- 5.93
- EPSi
- -0.54
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on ROIV?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 36.34, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year -71.57% YoY
Margins
- Gross margin
- 84.44%
- Operating margin
- -15,560.57%
- Net margin
- -3,629.19%
Key ratios & quality
- Altman Z-Scorei
- 36.34
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | 23.80M | 55.29M | 31.53M | 32.71M | 29.05M | 8.26M |
| Gross profit | 21.74M | 46.32M | 28.50M | 31.11M | 28.14M | 6.98M |
| Selling & admin expenses | 259.88M | 775.03M | 383.45M | 416.13M | 591.41M | 610.47M |
| Research & development | 236.63M | 483.04M | 454.06M | 439.91M | 550.41M | 681.81M |
| Operating profit | -474.77M | -1.21B | -809.01M | -824.93M | -1.11B | -1.29B |
| Pretax profit | -898.55M | -923.75M | -884.99M | 4.57B | -681.59M | -264.58M |
| Tax | 1.69M | 369.00K | 4.08M | 21.50M | 48.17M | 133.33M |
| Net profit | -900.23M | -924.12M | -1.12B | 4.23B | -356.73M | -397.91M |
| Basic EPS | -1 | -1 | -1 | 6 | 0 | 0 |
| Diluted EPS | -1.18 | -1.26 | -1.42 | 5.23 | -0.24 | -0.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 7.57M | 2.17M | 1.57M | 2.00M | 2.52M | 1.44M |
| Gross profit | 7.37M | 2.02M | 1.46M | 1.30M | 2.20M | 1.16M |
| Selling & admin expenses | 147.09M | 134.02M | 143.13M | 175.07M | 158.25M | 165.53M |
| Research & development | 145.24M | 152.92M | 164.57M | 165.38M | 198.95M | 202.02M |
| Operating profit | -284.97M | -284.92M | -306.23M | -339.15M | -355.00M | -366.39M |
| Pretax profit | -203.05M | -269.26M | -159.04M | -290.37M | 454.10M | -294.56M |
| Tax | 49.32M | 4.65M | 7.00M | 23.33M | 98.35M | -3.96M |
| Net profit | -252.38M | -273.91M | -166.04M | -313.70M | 355.74M | -290.61M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.29 | -0.33 | -0.17 | -0.38 | 0.28 | -0.26 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total current assets | 2.19B | 2.15B | 1.80B | 6.73B | 5.00B | 5.17B |
| Cash & ST investments | 2.06B | 2.06B | 1.68B | 6.49B | 4.89B | 4.29B |
| Inventory | -- | 0 | 2.76M | -- | -- | -- |
| Total assets | 2.59B | 2.59B | 2.39B | 7.22B | 5.44B | 5.71B |
| Total current liabilities | 218.96M | 184.37M | 272.45M | 266.76M | 149.41M | 281.24M |
| Short-term debt | 12.31M | 11.40M | 52.41M | 8.97M | 9.84M | 11.15M |
| Long-term debt | 170.28M | 210.03M | 375.52M | -- | -- | -- |
| Total liabilities | 527,687,000.00 | 523,695,000.00 | 782,017,000.00 | 773,953,000.00 | 249,742,000.00 | 416,275,000.00 |
| Total equity | 2.06B | 2.06B | 1.61B | 6.45B | 5.19B | 5.29B |
| Retained earnings | -1.92B | -2.76B | -3.77B | 576.17M | 116.06M | -501.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.00B | 4.62B | 4.51B | 4.66B | 5.17B | 4.74B |
| Cash & ST investments | 4.89B | 4.50B | 4.39B | 4.53B | 4.29B | 3.84B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 5.44B | 5.03B | 5.06B | 5.23B | 5.71B | 5.31B |
| Total current liabilities | 149.41M | 113.87M | 133.86M | 151.96M | 281.24M | 283.60M |
| Short-term debt | 9.84M | 9.40M | 9.00M | 10.44M | 11.15M | 12.38M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 249,742,000.00 | 216,696,000.00 | 257,140,000.00 | 251,144,000.00 | 416,275,000.00 | 384,624,000.00 |
| Total equity | 5.19B | 4.82B | 4.81B | 4.97B | 5.29B | 4.92B |
| Retained earnings | 116.06M | -315.59M | -429.11M | -695.00M | -501.81M | -900.35M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Operating cash flow | -552.14M | -677.73M | -843.39M | -765.27M | -839.45M | -750.35M |
| Depreciation & amortization | -- | 5.93M | 18.86M | 22.04M | 14.07M | 3.35M |
| Free cash flow | -557.94M | -695.17M | -856.08M | -766.65M | -844.05M | -758.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 455.76M | 0 | 379.71M | 438.56M | -1.18B | -125.90M |
| Ending cash balance | 2.14B | 2.07B | 1.69B | 6.55B | 2.73B | 1.43B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -172.57M | -204.38M | -185.66M | -196.48M | -163.82M | -270.50M |
| Depreciation & amortization | 1.43M | 1.10M | 921.00K | 691.00K | 638.00K | 600.00K |
| Free cash flow | -173.38M | -208.42M | -193.51M | -191.55M | -165.08M | -270.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -182.66M | -208.29M | 0 | 193.61M | -111.21M | -206.73M |
| Ending cash balance | 2.73B | 1.25B | 1.25B | 1.49B | 1.43B | 1.26B |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| ROE %i | -45.01 | -48.93 | -71.70 | 122.05 | -3.23 | -6.51 |
| ROA %i | -31.25 | -32.67 | -40.57 | 90.49 | -2.72 | -5.38 |
| ROIC %i | -39.56 | -42.17 | -56.56 | 104.54 | -6.50 | -9.20 |
| 5-year avg ROE %i | -- | -- | -- | -- | -9.36 | -1.66 |
| EBIT margin %i | -3,764.40 | -1,658.12 | -1,953.11 | 3,436.20 | -3,833.27 | -15,560.57 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.99 | 11.64 | 6.60 | 25.24 | 33.47 | 18.37 |
| Quick ratioi | 9.39 | 11.21 | 6.29 | 24.35 | 32.71 | 18.00 |
| Debt / assetsi | 9.46 | 10.98 | 20.15 | 0.75 | 1.84 | 1.88 |
| LT debt / equityi | 12.94 | 16.45 | 37.05 | 0.75 | 1.93 | 2.13 |
| Interest coveragei | -318.88 | -130.20 | -42.79 | 123.30 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 11.19 | -19.30 | -36.01 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.23 | -10.03 | -7.86 | -17.11 | -6.51 | -6.21 |
| ROA %i | -2.72 | -8.51 | -6.64 | -14.69 | -5.38 | -5.15 |
| ROIC %i | -6.50 | -12.99 | -11.00 | -19.71 | -9.20 | -8.91 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -3,833.27 | -5,104.73 | -5,659.41 | -9,130.53 | -15,560.57 | -18,146.12 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 33.47 | 40.54 | 33.70 | 30.66 | 18.37 | 16.72 |
| Quick ratioi | 32.71 | 39.55 | 32.77 | 29.81 | 18.00 | 16.27 |
| Debt / assetsi | 1.84 | 1.98 | 1.95 | 2.08 | 1.88 | 2.02 |
| LT debt / equityi | 1.93 | 2.08 | 2.06 | 2.31 | 2.13 | 2.24 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of medicines and technologies100.00%
Quote time 2026-10-08 08:13:38 · For reference only, not investment advice and not tailored to your situation.